Literature DB >> 22212915

Favourable prognosis in medulloblastoma with extensive nodularity is associated with mitogen-activated protein kinase upregulation.

Jarosław Jóźwiak1, Iwona Sontowska, Barbara Bikowska, Wiesława Grajkowska, Ryszard Galus, Marcin Roszkowski.   

Abstract

Medulloblastoma with extensive nodularity (MBEN) is the only type of medulloblastoma (MB), an aggressive CNS tumour of childhood, that is connected with favourable prognosis. In patients with MBEN tumour resection and chemotherapy are sometimes sufficient. While development of other types of MB is usually connected with activation of the wingless pathway, sonic hedgehog pathway or mammalian target of rapamycin (mTor) pathway, little is known about the molecular basis of MBEN pathophysiology. In the present paper we evaluated activation of the mTor pathway and kinases upstream of mTor, mitogen-activated protein kinase (MAPK/Erk) and protein kinase B (PKB/Akt) in an MBEN sample. Using western blot technique with antibodies directed against active, phosphorylated forms of proteins, we found upregulation of mTor, Akt and Erk. Thus we postulate that the mTor pathway, often implicated in the development of CNS tumours, is also responsible for MBEN progression. Especially interesting seems implication of Erk and other kinases belonging to the same pathway: mitogen-activated protein kinase kinase (MEK-1) or phospho-ribosomal S6 kinase-1 (p90 RSK1), whose activity we usually demonstrate in more benign neoplasms. However, it remains to be clarified whether Erk pathway activation is actually prognostic for benign tumour development.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22212915

Source DB:  PubMed          Journal:  Folia Neuropathol        ISSN: 1509-572X            Impact factor:   2.038


  6 in total

1.  CTGF expression is indicative of better survival rates in patients with medulloblastoma.

Authors:  Gustavo Alencastro Veiga Cruzeiro; Regia Caroline Peixoto Lira; Taciani de Almeida Magalhães; Carlos Alberto Scrideli; Elvis Terci Valera; Martin Baumgartner; Luiz Gonzaga Tone
Journal:  Cancer Gene Ther       Date:  2019-05-10       Impact factor: 5.987

2.  mTOR pathway as a potential target in a subset of human medulloblastoma.

Authors:  Tímea Pócza; Anna Sebestyén; Eszter Turányi; Tibor Krenács; Agnes Márk; Tamás Béla Sticz; Zsuzsanna Jakab; Péter Hauser
Journal:  Pathol Oncol Res       Date:  2014-04-16       Impact factor: 3.201

Review 3.  The rationale for targeted therapies in medulloblastoma.

Authors:  Tobey J MacDonald; Dolly Aguilera; Robert C Castellino
Journal:  Neuro Oncol       Date:  2013-12-04       Impact factor: 12.300

4.  Medulloblastoma: molecular pathways and histopathological classification.

Authors:  Anna Borowska; Jarosław Jóźwiak
Journal:  Arch Med Sci       Date:  2016-05-18       Impact factor: 3.318

5.  Atypical bilateral cerebellopontine angle medulloblastoma: differential diagnosis, immunohistochemical features and radiological presentation.

Authors:  Kelvin M Piña Batista; Sayoa Alvarez de Eulate-Beramendi; María Rico; Victor Rodrigo; Yordy E Batista Batista; Kenia Y Alvarez Reyes
Journal:  Contemp Oncol (Pozn)       Date:  2017-09-29

6.  Functional expression of calcium-permeable canonical transient receptor potential 4-containing channels promotes migration of medulloblastoma cells.

Authors:  Wei-Chun Wei; Wan-Chen Huang; Yu-Ping Lin; Esther B E Becker; Olaf Ansorge; Veit Flockerzi; Daniele Conti; Giovanna Cenacchi; Maike D Glitsch
Journal:  J Physiol       Date:  2017-07-20       Impact factor: 5.182

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.